Australia markets closed

BridgeBio Pharma, Inc. (BBIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
30.92+0.06 (+0.19%)
At close: 04:00PM EDT
31.00 +0.08 (+0.26%)
After hours: 07:35PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close30.86
Open30.78
Bid30.81 x 1500
Ask30.93 x 100
Day's range30.37 - 31.22
52-week range12.75 - 44.32
Volume1,797,915
Avg. volume1,806,644
Market cap5.703B
Beta (5Y monthly)1.05
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 16, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 16 new employees in restricted stock units for an aggregate of 71,146 shares of the Company’s common stock, with the effective date of March 18, 2024. One-fourth o

  • GlobeNewswire

    BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

    PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of $29.00 per share, before deducting underwriting discounts and commissions. In addition, BridgeBio has granted the underwriters a 30-day option to purchase up

  • GlobeNewswire

    BridgeBio Pharma Announces Proposed Public Offering of Common Stock

    PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it has commenced an underwritten public offering of $250 million of shares of its common stock. BridgeBio also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock. All of the shares in the proposed offering are t